8:00am – 9:00am    Poster Viewing 

9:00am – 9:45am    Plenary Speech: Professor Stephen Davis AO, MD  *Virtual
                   (University of Melbourne, Melbourne, Australia)

 Professor Stephen Davis AO, MD, FRCP Edin, FRACP, FAHMS
Title of Speech: Medical and surgical trials targeting the hematoma

Professor Stephen Davis is the Professor of Translational Neuroscience at the University of Melbourne, Director of the Melbourne Brain Centre at the Royal Melbourne Hospital. He is a Past-President of the World Stroke Organization, co-chairs the Australian Stroke Alliance and the Melbourne Mobile Stroke Unit.

He has received numerous awards including the 2011 William Feinberg Award from the American Stroke Association, the 2012 Karolinska Award and the 2014 JJ Wepfer Award from the European Stroke Council, 2018 Stroke Leadership Award from the WSO and the 2019 Chinese Stroke Association International Cooperation Award. He was an inaugural Fellow in the Australian Academy of Health and Medical Sciences, 2015 and the 2017 C Miller Fisher Visiting Professor at the Massachusetts General Hospital/Harvard. He was appointed an Officer of the Order of Australia in 2021.

His research is focussed on acute therapy for both ischemic stroke and intracerebral haemorrhage, particularly the use of advanced imaging in selection of therapy. He is the Principal Investigator of a MRFF grant using tranexamic acid for intracerebral hemorrhage and Co-Lead (with G Donnan) of the 2021 Frontiers MRFF grant on Pre-Hospital Stroke Care. He has published more than 550 peer-reviewed research 

 
Coffee break (15 min)

10:00am – 12:00pm   3. Theme (full session) Perivascular clearance, vasomotion, and CAA *Moderator: Susanne Van Veluw, PhD, Harvard Medical School, Boston, USA

• MR imaging of glymphatic clearance in animal models  *Virtual
    – Helene Benveniste, MD, PhD, Yale School of Medicine, New Haven, USA 
•  
• Anatomy of the perivascular compartment 
    – Andy Shih, PhD, Center for Developmental Biology and Regenerative Medicine, University of Washington, Washington, USA
•  
• Physiologic drivers of lymphatic clearance 
    – Deidre Jansson, MSc, PhD, School of Biological Sciences University of Auckland, Auckland, New Zealand
•  
• MR imaging of CSF mobility and vasomotion in humans 
    – Lydiane Hirschler PhD, Leiden University Medical Center, Leiden, Netherlands
•  
• Selected Oral Abstracts
• #1: C. Chen.  *Virtual

  Longitudinal decrease in cerebrovascular reactivity to carbon dioxide in cerebral amyloid angiopathy

• #2: L. Sveikata.  *Virtual

  Long-term Blood Pressure Variability is Associated with White Matter Microstructural Integrity in CAA #3: A. Urayama Reorganization of Tight Junction through Mechanosensitive Signals in Brain Endothelia

12:00pm – 1:00pm    Lunch break/Poster Viewing

1:00pm – 2:45pm      4. Theme (half session) Innovative therapeutic approaches 
*Moderator: Samantha Gardener, PhD, Edith Cowan University, Australia

• Fibrinolytic targets 
    – Geoffrey Cloud, MD, PhD, Alfred Hospital, Melbourne, Australia
•  
• Cutting-Edge Therapeutic Approaches to Cerebral Amyloid Angiopathy *Virtual
    – Yasuteru Inoue, MD, PhD, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan

The neuroepidemiology of sporadic CAA, evidence from two large population-based autopsy series: the Honolulu-Asia Study and the Nun Study. *Virtual
  – Steven Edland, PhD, University of California, San Diego, USA. 

Recent therapeutic advances in genetic ALS: learnings from SODI and C9orf72 ALS trials
  – Toby Ferguson, MD, PhD, Vice President, Head Neuromuscular Development Unit, Biogen, USA


Selected Oral Abstracts
#1: O. Bonnar

• #2: R. Che

  Remote Ischemic Conditioning —— a Novel Intervention to Lessen CAA #3: L. Jäkel Prevalence of sporadic CAA in East Asian versus Western populations: A Meta-Analysis  Coffee break (15 min)

3:00pm – 5:30pm       5. Theme (full session) Clinical diagnosis and treatment: ICAAA Guidelines *Moderator: Steven Greenberg, MD, PhD, Harvard Medical School, Boston, USA

Diagnosis and treatment of CAA-related inflammation/ vasculitis  *Virtual
 – David Werring, MD, PhD, National Hospital of Neurology and Neurosurgery, London, UK

•  
• Diagnosis, testing and prediction of ICH risk
•   – Eric Smith, MD, FRCPC, MPH, University of Calgary, Calgary, Canada – 
•  
• Treatments/ interventions: Use of anti thrombotic agents  *Virtual
•   – Karin Klijn, MD, PhD, Radboud University Medical Center, Nijmegen, Netherlands
•  
• Treatments/ interventions: Blood pressure, other medications, lifestyl. *Virtual
•   – Charlotte Cordonnier MD, PhD, CHU Lille, Lille, France
•   
• Organisation of website, additional materials, future updating and publication
    – Susanne Van Veluw, PhD; Harvard Medical School, Boston, USA
•   – Steven Greenberg, MD, PhD, Harvard Medical School, Boston, USA

5:30pm – 6:00pm: Poster Viewing